{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:46:18Z","timestamp":1792932378425,"version":"4.5.0"},"reference-count":240,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00203-025-04298-z","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:54:23Z","timestamp":1743753263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms"],"prefix":"10.1007","volume":"207","author":[{"given":"Sena Nur","family":"Ba\u015faran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00fctfiye","family":"\u00d6ks\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"4298_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M, Olafisoye O, Cortes C et al (2015) Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 59:1802\u20131805. https:\/\/doi.org\/10.1128\/AAC.04809-14","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.51847\/wqUTf4VfuO","volume":"12","author":"RS Abou-assy","year":"2023","unstructured":"Abou-assy RS, Aly MM, Amasha RH et al (2023) Carbapenem resistance mechanisms, carbapenemase genes dissemination, and laboratory detection methods: a review. Int J Pharm Rese Allied Sci 12:123\u2013138","journal-title":"Int J Pharm Rese Allied Sci"},{"key":"4298_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ma15165709","author":"AS Abu Lila","year":"2022","unstructured":"Abu Lila AS, Huwaimel B, Alobaida A et al (2022) Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): an effective antibacterial nano-formulation of fluoroquinolone antibiotic. Materials. https:\/\/doi.org\/10.3390\/ma15165709","journal-title":"Materials"},{"key":"4298_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2020.100971","author":"MA Abushaheen","year":"2020","unstructured":"Abushaheen MA, Muzaheed FAJ et al (2020) Antimicrobial resistance, mechanisms and its clinical significance. Dis Mon. https:\/\/doi.org\/10.1016\/j.disamonth.2020.100971","journal-title":"Dis Mon"},{"key":"4298_CR5","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1128\/AAC.00572-10","volume":"54","author":"JB Aggen","year":"2010","unstructured":"Aggen JB, Armstrong ES, Goldblum AA et al (2010) Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54:4636\u20134642. https:\/\/doi.org\/10.1128\/AAC.00572-10","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106887","author":"AA Agyeman","year":"2023","unstructured":"Agyeman AA, L\u00f3pez-Causap\u00e9 C, Rogers KE et al (2023) Ceftolozane\/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106887","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3855\/jidc.12368","volume":"14","author":"GF Araj","year":"2020","unstructured":"Araj GF, Berjawi DM, Musharrafieh U, Beayni NKE (2020) Activity of ceftolozane\/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon. J Infect Dev Ctries 14:559\u2013564. https:\/\/doi.org\/10.3855\/jidc.12368","journal-title":"J Infect Dev Ctries"},{"key":"4298_CR8","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/jac\/dkaa291","volume":"75","author":"J Arca-Su\u00e1rez","year":"2020","unstructured":"Arca-Su\u00e1rez J, V\u00e1zquez-Ucha JC, Fraile-Ribot PA et al (2020) Molecular and biochemical insights into the in vivo evolution of ampc-mediated resistance to ceftolozane\/tazobactam during treatment of an MDR pseudomonas aeruginosa infection. J Antimicrob Chemother 75:3209\u20133217. https:\/\/doi.org\/10.1093\/jac\/dkaa291","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR9","doi-asserted-by":"publisher","first-page":"106456","DOI":"10.1016\/j.ijantimicag.2021.106456","volume":"59","author":"J Arca-Su\u00e1rez","year":"2022","unstructured":"Arca-Su\u00e1rez J, Rodi\u00f1o-Janeiro BK, P\u00e9rez A et al (2022) Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing. Int J Antimicrob Agents 59:106456","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.54962\/ankemderg.1349997","volume":"37","author":"N Ar\u0131c\u0131","year":"2023","unstructured":"Ar\u0131c\u0131 N, Kansak N, Adaleti R et al (2023) In vitro activity of ceftazidime-avibactam against carbapenem-resistant klebsiella pneumoniae and pseudomonas aeruginosa isolates in ventilator-associated pneumonia. ANKEM J 37:57\u201364","journal-title":"ANKEM J"},{"key":"4298_CR11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/AAC.02102-15","volume":"60","author":"A Asli","year":"2016","unstructured":"Asli A, Brouillette E, Krause KM et al (2016) Distinctive binding of avibactam to penicillin-binding proteins of gram-negative and gram-positive bacteria. Antimicrob Agents Chemother 60:752\u2013756. https:\/\/doi.org\/10.1128\/AAC.02102-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1089\/mdr.2018.0065","volume":"24","author":"G Balabanian","year":"2018","unstructured":"Balabanian G, Rose M, Manning N et al (2018) Effect of porins and blaKPC expression on activity of imipenem with relebactam in klebsiella pneumoniae: Can antibiotic combinations overcome resistance? Microb Drug Resist 24:877\u2013881. https:\/\/doi.org\/10.1089\/mdr.2018.0065","journal-title":"Microb Drug Resist"},{"key":"4298_CR13","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.3390\/ijms24065777","volume":"24","author":"A Baran","year":"2023","unstructured":"Baran A, Kwiatkowska A, Potocki L (2023) Antibiotics and bacterial resistance\u2014a short story of an endless arms race. Int J Mol Sci 24:5777","journal-title":"Int J Mol Sci"},{"key":"4298_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-17","author":"MD Barnes","year":"2018","unstructured":"Barnes MD, Bethel CR, Alsop J et al (2018) Inactivation of the pseudomonas-derived cephalosporinase-3 (PDC-3) by Relebactam. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02406-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR15","doi-asserted-by":"publisher","unstructured":"Barnes MD, Winkler ML, Taracila MA, et al (2017) Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from-Lactamase Protein Engineering. https:\/\/doi.org\/10.1128\/mBio","DOI":"10.1128\/mBio"},{"key":"4298_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10096-021-04341-z","volume":"41","author":"G Bianco","year":"2022","unstructured":"Bianco G, Boattini M, Comini S et al (2022) In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects. Eur J Clin Microbiol Infect Dis 41:63\u201370. https:\/\/doi.org\/10.1007\/s10096-021-04341-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4298_CR17","doi-asserted-by":"publisher","first-page":"14132","DOI":"10.3390\/cimb46120846","volume":"46","author":"G Bianco","year":"2024","unstructured":"Bianco G, Boattini M, Cricca M et al (2024) Updates on the activity, efficacy and emerging mechanisms of resistance to cefiderocol. Curr Issues Mol Biol 46:14132\u201314153","journal-title":"Curr Issues Mol Biol"},{"key":"4298_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.922976","author":"I Bitar","year":"2022","unstructured":"Bitar I, Salloum T, Merhi G et al (2022) Genomic characterization of mutli-drug resistant pseudomonas aeruginosa clinical isolates: evaluation and determination of ceftolozane\/tazobactam activity and resistance mechanisms. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2022.922976","journal-title":"Front Cell Infect Microbiol"},{"key":"4298_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01625-22","author":"A B\u00f6sch","year":"2023","unstructured":"B\u00f6sch A, Macha ME, Ren Q et al (2023) Resistance development in Escherichia coli to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01625-22","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR20","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/JAC\/DKX179","volume":"72","author":"A Both","year":"2017","unstructured":"Both A, B\u00fcttner H, Huang J et al (2017) Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother 72:2483\u20132488. https:\/\/doi.org\/10.1093\/JAC\/DKX179","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab353","author":"E Bouza","year":"2021","unstructured":"Bouza E (2021) The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections. J Antimicrobial Chemotherapy. https:\/\/doi.org\/10.1093\/jac\/dkab353","journal-title":"J Antimicrobial Chemotherapy"},{"key":"4298_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01076-18","author":"K Bush","year":"2018","unstructured":"Bush K (2018) Past and present perspectives on \u03b2-lactamases. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01076-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","volume":"17","author":"K Bush","year":"2019","unstructured":"Bush K, Bradford PA (2019) Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors. Nat Rev Microbiol 17:295\u2013306","journal-title":"Nat Rev Microbiol"},{"key":"4298_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1128\/AAC.31.8.1271","volume":"31","author":"K Bush","year":"1987","unstructured":"Bush K, Smith SA, Ohringer S et al (1987) Improved sensitivity in assays for binding of Novel 3-lactam antibiotics to penicillin-binding proteins of escherichia coli. Antimicrob Agents Chemother 31:1271","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR25","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/AAC.02462-13","volume":"58","author":"G Cabot","year":"2014","unstructured":"Cabot G, Bruchmann S, Mulet X et al (2014) Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of ampc. Antimicrob Agents Chemother 58:3091\u20133099. https:\/\/doi.org\/10.1128\/AAC.02462-13","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jgar.2019.11.007","volume":"22","author":"\u00c1 Cano","year":"2020","unstructured":"Cano \u00c1, Guzm\u00e1n-Puche J, Garc\u00eda-Guti\u00e9rrez M et al (2020) Use of carbapenems in the combined treatment of emerging ceftazidime\/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature. J Glob Antimicrob Resist 22:9\u201312. https:\/\/doi.org\/10.1016\/j.jgar.2019.11.007","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661\u2013673. https:\/\/doi.org\/10.1016\/S1473-3099(16)30004-4","journal-title":"Lancet Infect Dis"},{"key":"4298_CR28","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0277-2022","author":"TN Carvalho","year":"2023","unstructured":"Carvalho TN, Kobs VC, Hille D et al (2023) Evaluation of in-vitro susceptibility of \u00df-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozanetazobactam from clinical samples of a general hospital in southern Brazil. Rev Soc Bras Med Trop. https:\/\/doi.org\/10.1590\/0037-8682-0277-2022","journal-title":"Rev Soc Bras Med Trop"},{"key":"4298_CR29","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/jac\/dky344","volume":"73","author":"M Castanheira","year":"2018","unstructured":"Castanheira M, Deshpande LM, Woosley LN et al (2018) Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother 73:3346\u20133354. https:\/\/doi.org\/10.1093\/jac\/dky344","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2018.10.023","volume":"94","author":"M Castanheira","year":"2019","unstructured":"Castanheira M, Davis AP, Serio AW et al (2019) In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. Diagn Microbiol Infect Dis 94:73\u201377. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.10.023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4298_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01951-19","author":"M Castanheira","year":"2020","unstructured":"Castanheira M, Doyle TB, Kantro V et al (2020a) Meropenem-vaborbactam activity against carbapenem-resistant enterobacterales isolates collected in U.S. Hospitals during 2016 to 2018. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01951-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106439","author":"M Castanheira","year":"2021","unstructured":"Castanheira M, Doyle TB, Deshpande LM et al (2021a) Activity of ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106439","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR33","doi-asserted-by":"crossref","unstructured":"Castanheira M, Sader HS, Mendes RE, Jones RN (2020b) Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016\u20132017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides","DOI":"10.1128\/AAC.02418-19"},{"key":"4298_CR34","doi-asserted-by":"crossref","unstructured":"Castanheira M, Simner PJ, Bradford PA (2021b) Extended-spectrum \u03b2-lactamases: An update on their characteristics, epidemiology and detection. JAC Antimicrob Resist 3","DOI":"10.1093\/jacamr\/dlab092"},{"key":"4298_CR35","unstructured":"CDC (2019) Centers for Disease Control and Prevention: antibiotic resistance threats in the United States, Atlanta, GA. https:\/\/ndc.services.cdc.gov\/wp-content\/uploads\/Antibiotic-Resistance-Threats-in-the-United-States-2019.pdf. Accessed 20 Feb 2025"},{"key":"4298_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep40208","author":"H Chalhoub","year":"2017","unstructured":"Chalhoub H, Pletzer D, Weingart H et al (2017) Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. Sci Rep. https:\/\/doi.org\/10.1038\/srep40208","journal-title":"Sci Rep"},{"key":"4298_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ijantimicag.2018.07.027","volume":"52","author":"H Chalhoub","year":"2018","unstructured":"Chalhoub H, S\u00e1enz Y, Nichols WW et al (2018) Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. Int J Antimicrob Agents 52:697\u2013701. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.027","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120952604","author":"JA Clark","year":"2020","unstructured":"Clark JA, Burgess DS (2020) Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance. Ther Adv Infect Dis. https:\/\/doi.org\/10.1177\/2049936120952604","journal-title":"Ther Adv Infect Dis"},{"key":"4298_CR39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00451-17","author":"F Compain","year":"2017","unstructured":"Compain F, Arthur M (2017) Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 \u03b2-lactamase. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00451-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00357-18","author":"F Compain","year":"2018","unstructured":"Compain F, Dorch\u00e8ne D, Arthur M (2018) Combination of amino acid substitutions leading to CTX-M-15-mediated resistance to the ceftazidime-avibactam combination. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00357-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR41","unstructured":"Coppi M, Pilato V Di, Monaco F, et al (2020) Ceftazidime-Avibactam Resistance Associated with Increased bla KPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae"},{"key":"4298_CR42","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1021\/acsinfecdis.8b00001","volume":"4","author":"G Cox","year":"2018","unstructured":"Cox G, Ejim L, Stogios PJ et al (2018) Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis 4:980\u2013987. https:\/\/doi.org\/10.1021\/acsinfecdis.8b00001","journal-title":"ACS Infect Dis"},{"key":"4298_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.884365","author":"F Cruz-L\u00f3pez","year":"2022","unstructured":"Cruz-L\u00f3pez F, Mart\u00ednez-Mel\u00e9ndez A, Morfin-Otero R et al (2022) Efficacy and in vitro activity of novel antibiotics for infections with carbapenem-resistant Gram-negative pathogens. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2022.884365","journal-title":"Front Cell Infect Microbiol"},{"key":"4298_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01365","author":"X Cui","year":"2020","unstructured":"Cui X, Shan B, Zhang X et al (2020) Reduced ceftazidime-avibactam susceptibility in KPC-producing klebsiella pneumoniae from patients without ceftazidime-avibactam use history \u2013 a multicenter study in China. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2020.01365","journal-title":"Front Microbiol"},{"key":"4298_CR45","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","volume":"60","author":"BLM De Jonge","year":"2016","unstructured":"De Jonge BLM, Karlowsky JA, Kazmierczak KM et al (2016) In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 60:3163\u20133169. https:\/\/doi.org\/10.1128\/AAC.03042-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106361","author":"T Delory","year":"2021","unstructured":"Delory T, Gravier S, Le Pluart D et al (2021) Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106361","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","volume":"25","author":"S Di Bella","year":"2021","unstructured":"Di Bella S, Giacobbe DR, Maraolo AE et al (2021) Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. J Glob Antimicrob Resist 25:268\u2013281","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac132","author":"A Dinh","year":"2023","unstructured":"Dinh A, Duran C, Singh S et al (2023) Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: A multicentre retrospective study. JAC Antimicrob Resist. https:\/\/doi.org\/10.1093\/jacamr\/dlac132","journal-title":"JAC Antimicrob Resist"},{"key":"4298_CR49","doi-asserted-by":"crossref","unstructured":"Dulyayangkul P, Kamil WA, Ismah WN, et al (2020) Mutation of kvrA Causes OmpK35 and OmpK36 Porin Downregulation and Reduced Meropenem-Vaborbactam Susceptibility in KPC-Producing Klebsiella pneumoniae","DOI":"10.1101\/845925"},{"key":"4298_CR50","unstructured":"ECDC (2018) European Centre for Disease Prevention and Control:Surveillance of antimicrobial resistance in Europe 2018. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2018. Accessed 20 Feb 2025"},{"key":"4298_CR51","unstructured":"ECDC (2018) Emergence of Resistance to Ceftazidime-avibactam in Carbapenem- Resistant Enterobacteriaceae"},{"key":"4298_CR52","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1473-3099(21)00407-2","volume":"22","author":"C Edlund","year":"2021","unstructured":"Edlund C, Ternhag A, Skoog St\u00e5hlgren G et al (2021) The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden. Lancet Infect Dis 22:390\u2013400","journal-title":"Lancet Infect Dis"},{"key":"4298_CR53","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"DE Ehmann","year":"2013","unstructured":"Ehmann DE, Jahi\u0107 H, Ross PL et al (2013) Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases. J Biol Chem 288:27960\u201327971. https:\/\/doi.org\/10.1074\/jbc.M113.485979","journal-title":"J Biol Chem"},{"key":"4298_CR54","unstructured":"Elbouseary M, Walsh TR (2017) Comparative in-vitro activity of Eravacycline, a novel fluorocycline, against mcr-1-positive Escherichia coli and Klebsiella pneumoniae"},{"key":"4298_CR55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","volume":"79","author":"K Eljaaly","year":"2019","unstructured":"Eljaaly K, Alharbi A, Alshehri S et al (2019) Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections. Drugs 79:243\u2013269","journal-title":"Drugs"},{"key":"4298_CR56","doi-asserted-by":"publisher","DOI":"10.18502\/ijm.v13i6.8080","author":"M El-Sayed Mashaly","year":"2021","unstructured":"El-Sayed Mashaly M, El-Saeed Mashaly G (2021) OXA-48 Activity of imipenem\/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility. Iranian J Microbiol. https:\/\/doi.org\/10.18502\/ijm.v13i6.8080","journal-title":"Iranian J Microbiol"},{"key":"4298_CR57","unstructured":"European Medicines Agency (2020) Recarbrio: EPAR-public assessment report 2020. https:\/\/www.ema.europa.eu\/en\/homepage. Accessed 17 Mar 2024"},{"key":"4298_CR58","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Tiseo G, Nicastro M et al (2021) Cefiderocol as rescue therapy for acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients. Clin Infect Dis 72:2021\u20132024. https:\/\/doi.org\/10.1093\/cid\/ciaa1410","journal-title":"Clin Infect Dis"},{"key":"4298_CR59","doi-asserted-by":"publisher","unstructured":"Fan KC, Lin J, Yannuzzi NA, et al (2020) In vitro Susceptibilities of Methicillin-Susceptible and Resistant Staphylococci to Traditional Antibiotics Compared to a Novel Fluoroquinolone. J Ophthalmic Inflamm Infect 10:. https:\/\/doi.org\/10.1186\/s12348-020-0200-0","DOI":"10.1186\/s12348-020-0200-0"},{"key":"4298_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115368","author":"E Farfour","year":"2021","unstructured":"Farfour E, Si Larbi AG, Cattoir V et al (2021) Temocillin susceptibility among Enterobacterales strains recovered from blood culture in France. Diagn Microbiol Infect Dis. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115368","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4298_CR62","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.eimc.2020.01.017","volume":"38","author":"M Fern\u00e1ndez-Esgueva","year":"2020","unstructured":"Fern\u00e1ndez-Esgueva M, L\u00f3pez-Calleja AI, Mulet X et al (2020) Characterization of AmpC \u03b2-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane\/tazobactam during therapy. Enferm Infecc Microbiol Clin 38:474\u2013478. https:\/\/doi.org\/10.1016\/j.eimc.2020.01.017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4298_CR63","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1093\/jac\/dkad243","volume":"78","author":"J Findlay","year":"2023","unstructured":"Findlay J, Poirel L, Nordmann P (2023) Rapid detection of temocillin resistance in Enterobacterales. J Antimicrob Chemother 78:2770\u20132771. https:\/\/doi.org\/10.1093\/jac\/dkad243","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR64","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jac\/dkx424","volume":"73","author":"PA Fraile-Ribot","year":"2018","unstructured":"Fraile-Ribot PA, Cabot G, Mulet X et al (2018) Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother 73:658\u2013663. https:\/\/doi.org\/10.1093\/jac\/dkx424","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR65","doi-asserted-by":"publisher","unstructured":"Fraile-Ribot PA, Mulet X, Cabot G, et al (2017) In Vivo Emergence of Resistance to Novel Cephalosporin-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. https:\/\/doi.org\/10.1128\/AAC","DOI":"10.1128\/AAC"},{"key":"4298_CR66","doi-asserted-by":"crossref","unstructured":"Fraile-Ribot PA, del Rosario-Quintana C, L\u00f3pez-Causap\u00e9 C, et al (2020a) Emergence of Resistance to Novel \u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308. Antimicrob Agents Chemother 64","DOI":"10.1128\/AAC.02112-19"},{"key":"4298_CR67","unstructured":"Fraile-Ribot PA, Zamorano L, Orellana R, et al (2020b) Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic-Lactam-Resistant Mutants"},{"key":"4298_CR68","doi-asserted-by":"publisher","DOI":"10.1128\/JCM","author":"R Friedrich","year":"2018","unstructured":"Friedrich R, Rappold E, Bogdan C, Held J (2018) Comparative analysis of the wako \u0392-glucan test and the fungitell assay for diagnosis of candidemia and Pneumocystis jirovecii pneumonia. J Clin Microbiol. https:\/\/doi.org\/10.1128\/JCM","journal-title":"J Clin Microbiol"},{"key":"4298_CR69","doi-asserted-by":"publisher","first-page":"6989","DOI":"10.1128\/AAC.01646-16","volume":"60","author":"C Fyfe","year":"2016","unstructured":"Fyfe C, LeBlanc G, Close B et al (2016) Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1. Antimicrob Agents Chemother 60:6989\u20136990","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR70","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/jac\/dky082","volume":"73","author":"P Gaibani","year":"2018","unstructured":"Gaibani P, Campoli C, Lewis RE et al (2018) In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment. J Antimicrob Chemother 73:1525\u20131529. https:\/\/doi.org\/10.1093\/jac\/dky082","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR71","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/jac\/dkaa079","volume":"75","author":"P Gaibani","year":"2020","unstructured":"Gaibani P, Lombardo D, Foschi C et al (2020) Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring bla KPC variants associated with ceftazidime\/avibactam resistance. J Antimicrob Chemother 75:2010\u20132013","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijid.2021.10.028","volume":"113","author":"P Gaibani","year":"2021","unstructured":"Gaibani P, Gatti M, Rinaldi M et al (2021) Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient. Int J Infect Dis 113:213\u2013217. https:\/\/doi.org\/10.1016\/j.ijid.2021.10.028","journal-title":"Int J Infect Dis"},{"key":"4298_CR73","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00191-22","author":"P Gaibani","year":"2022","unstructured":"Gaibani P, Bianco G, Amadesi S et al (2022a) Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem\/ Relebactam and Meropenem\/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00191-22","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR74","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/jac\/dkac100","volume":"77","author":"P Gaibani","year":"2022","unstructured":"Gaibani P, Bovo F, Bussini L et al (2022b) Dynamic evolution of imipenem\/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime\/avibactam-based treatments. J Antimicrob Chemother 77:1570\u20131577. https:\/\/doi.org\/10.1093\/jac\/dkac100","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR75","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/antibiotics11050628","volume":"11","author":"P Gaibani","year":"2022","unstructured":"Gaibani P, Giani T, Bovo F et al (2022c) Resistance to Ceftazidime\/Avibactam, Meropenem\/Vaborbactam and Imipenem\/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics 11:628","journal-title":"Antibiotics"},{"key":"4298_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3801-1","author":"I Galani","year":"2019","unstructured":"Galani I, Nafplioti K, Adamou P et al (2019a) Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis. https:\/\/doi.org\/10.1186\/s12879-019-3801-1","journal-title":"BMC Infect Dis"},{"key":"4298_CR77","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s10096-019-03517-y","volume":"38","author":"I Galani","year":"2019","unstructured":"Galani I, Souli M, Nafplioti K et al (2019b) In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015\u20132016. Eur J Clin Microbiol Infect Dis 38:1143\u20131150. https:\/\/doi.org\/10.1007\/s10096-019-03517-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4298_CR78","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","volume":"16","author":"DR Giacobbe","year":"2018","unstructured":"Giacobbe DR, Bassetti M, De Rosa FG et al (2018) Ceftolozane\/tazobactam: place in therapy. Expert Rev Anti Infect Ther 16:307\u2013320","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4298_CR79","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02101-17","author":"MJ Giddins","year":"2018","unstructured":"Giddins MJ, Macesic N, Annavajhala MK et al (2018) Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02101-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR80","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/fmb-2021-0202","volume":"17","author":"A Giedraitiene","year":"2022","unstructured":"Giedraitiene A, Pereckaite L, Bredelyte-Gruodiene E et al (2022) CTX-M-producing Escherichia coli strains: Resistance to temocillin, fosfomycin, nitrofurantoin and biofilm formation. Future Microbiol 17:789\u2013802. https:\/\/doi.org\/10.2217\/fmb-2021-0202","journal-title":"Future Microbiol"},{"key":"4298_CR81","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","volume":"21","author":"CG Giske","year":"2015","unstructured":"Giske CG (2015) Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect 21:899\u2013905","journal-title":"Clin Microbiol Infect"},{"key":"4298_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02261-4","author":"T Golkar","year":"2021","unstructured":"Golkar T, Bassenden AV, Maiti K et al (2021) Structural basis for plazomicin antibiotic action and resistance. Commun Biol. https:\/\/doi.org\/10.1038\/s42003-021-02261-4","journal-title":"Commun Biol"},{"key":"4298_CR83","doi-asserted-by":"crossref","unstructured":"Gomez-Simmonds A, Stump S, Giddins MJ, et al (2018) Clonal Background, Resistance Gene Profile, and Porin Gene Mutations Modulate In Vitro Susceptibility to Imipenem-Relebactam in Diverse Enterobacteriaceae","DOI":"10.1128\/AAC.00573-18"},{"key":"4298_CR84","doi-asserted-by":"publisher","unstructured":"Gomis-Font MA, Pitart C, Del Barrio-Tofi\u00f1o E, et al (2021) Emergence of resistance to novel cephalosporin-b-lactamase inhibitor combinations through the modification of the pseudomonas aeruginosa MexCD-OprJ Efflux Pump. https:\/\/doi.org\/10.1128\/AAC","DOI":"10.1128\/AAC"},{"key":"4298_CR85","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH, Starosta AL, Fyfe C et al (2012) Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559\u20132564. https:\/\/doi.org\/10.1128\/AAC.06187-11","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR86","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00358-23","author":"F Gu\u00e9rin","year":"2023","unstructured":"Gu\u00e9rin F, Gravey F, Reissier S et al (2023) Temocillin resistance in the enterobacter cloacae complex is conferred by a single point mutation in baes leading to overexpression of the AcrD Efflux Pump. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00358-23","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061602","author":"D Guly\u00e1s","year":"2023","unstructured":"Guly\u00e1s D, Kamotsay K, Szab\u00f3 D, Kocsis B (2023) Investigation of delafloxacin resistance in multidrug-resistant escherichia coli strains and the detection of E. coli ST43 International High-Risk Clone. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms11061602","journal-title":"Microorganisms"},{"key":"4298_CR88","doi-asserted-by":"publisher","DOI":"10.5812\/jjm-134090","author":"G Hazirolan","year":"2023","unstructured":"Hazirolan G, \u00d6zkul C (2023) Evaluation of in vitro activity of ceftolozane\/tazobactam and ceftazidime\/avibactam against carbapenem-resistant pseudomonas aeruginosa strains and mechanisms of carbapenem resistance: data from tertiary care hospital. Jundishapur J Microbiol. https:\/\/doi.org\/10.5812\/jjm-134090","journal-title":"Jundishapur J Microbiol"},{"key":"4298_CR89","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/1060028019850173","volume":"53","author":"M Heaney","year":"2019","unstructured":"Heaney M, Mahoney MV, Gallagher JC (2019) Eravacycline: the tetracyclines strike back. Ann Pharmacother 53:1124\u20131135","journal-title":"Ann Pharmacother"},{"key":"4298_CR90","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jac\/dkz026","volume":"74","author":"P Hemarajata","year":"2019","unstructured":"Hemarajata P, Humphries RM (2019) Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother 74:1241\u20131243. https:\/\/doi.org\/10.1093\/jac\/dkz026","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR91","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40265-021-01471-8","volume":"81","author":"YA Heo","year":"2021","unstructured":"Heo YA (2021) Imipenem\/cilastatin\/relebactam: a review in Gram-negative bacterial infections. Drugs 81:377\u2013388","journal-title":"Drugs"},{"key":"4298_CR92","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/antibiotics13060472","volume":"13","author":"T Hillyer","year":"2024","unstructured":"Hillyer T, Shin WS (2024) Meropenem\/vaborbactam\u2014a mechanistic review for insight into future development of combinational therapies. Antibiotics 13:472. https:\/\/doi.org\/10.3390\/antibiotics13060472","journal-title":"Antibiotics"},{"key":"4298_CR93","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jgar.2020.04.017","volume":"22","author":"EB Hirsch","year":"2020","unstructured":"Hirsch EB, Brigman HV, Zucchi PC et al (2020) Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres. J Glob Antimicrob Resist 22:689\u2013694. https:\/\/doi.org\/10.1016\/j.jgar.2020.04.017","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR94","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00031-19","author":"JP Horcajada","year":"2019","unstructured":"Horcajada JP, Montero M, Oliver A et al (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/CMR.00031-19","journal-title":"Clin Microbiol Rev"},{"key":"4298_CR95","doi-asserted-by":"publisher","DOI":"10.26650\/IUITFD.1092556","author":"T Ho\u015fbul","year":"2022","unstructured":"Ho\u015fbul T, Aydo\u011fan C, Kaya S et al (2022) In vitro activity of ceftazidime-avibactam and colistin against carbapenem-resistant pseudomonas aeruginosa clinical isolates. Journal of Istanbul. https:\/\/doi.org\/10.26650\/IUITFD.1092556","journal-title":"Journal of Istanbul"},{"key":"4298_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031026","author":"W Huang","year":"2020","unstructured":"Huang W, El Hamouche J, Wang G et al (2020) Integrated genome-wide analysis of an isogenic pair of pseudomonas aeruginosa clinical isolates with differential antimicrobial resistance to ceftolozane\/tazobactam, ceftazidime\/avibactam, and piperacillin\/tazobactam. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21031026","journal-title":"Int J Mol Sci"},{"key":"4298_CR97","doi-asserted-by":"crossref","unstructured":"Humphries RM, Hemarajata P (2017) Resistance to ceftazidime-Avibactam in klebsiella pneumoniae due to porin mutations & the increased expression of KPC-3. Antimicrob Agents Chemother 61","DOI":"10.1128\/AAC.00537-17"},{"key":"4298_CR98","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/cid\/ciz787","volume":"70","author":"A Iregui","year":"2020","unstructured":"Iregui A, Khan Z, Malik S et al (2020) Emergence of delafloxacin-resistant staphylococcus aureus in brooklyn, New York. Clin Infect Dis 70:1758\u20131760. https:\/\/doi.org\/10.1093\/cid\/ciz787","journal-title":"Clin Infect Dis"},{"key":"4298_CR99","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/23744235.2023.2226709","volume":"55","author":"B Isler","year":"2023","unstructured":"Isler B, Vatansever C, \u00d6zer B et al (2023) Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints. Infect Dis 55:607\u2013613. https:\/\/doi.org\/10.1080\/23744235.2023.2226709","journal-title":"Infect Dis"},{"key":"4298_CR100","doi-asserted-by":"crossref","unstructured":"Jacobs MR, Abdelhamed AM, Good CE, et al (2018) ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum-Lactamases and Carbapenemases","DOI":"10.1128\/AAC.01801-18"},{"key":"4298_CR101","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/nejmoa1914433","volume":"382","author":"JA Jernigan","year":"2020","unstructured":"Jernigan JA, Hatfield KM, Wolford H et al (2020) Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012\u20132017. N Engl J Med 382:1309\u20131319. https:\/\/doi.org\/10.1056\/nejmoa1914433","journal-title":"N Engl J Med"},{"key":"4298_CR102","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00797-20","author":"BD Johnston","year":"2020","unstructured":"Johnston BD, Thuras P, Porter SB et al (2020) Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant escherichia coli isolates from the united states and international sites in relation to clonal background, resistance genes, coresistance, and region. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00797-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR103","doi-asserted-by":"publisher","first-page":"197","DOI":"10.6084\/m9.figshare.59992","volume":"7","author":"J Jorgensen Nicholas","year":"2018","unstructured":"Jorgensen Nicholas J, Mercuro Susan J, Davis Michael L et al (2018) Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther 7:197\u2013217. https:\/\/doi.org\/10.6084\/m9.figshare.59992","journal-title":"Infect Dis Ther"},{"key":"4298_CR104","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/phar.2092","volume":"38","author":"SCJ Jorgensen","year":"2018","unstructured":"Jorgensen SCJ, Rybak MJ (2018) Meropenem and vaborbactam: stepping up the battle against carbapenem-resistant enterobacteriaceae. Pharmacotherapy 38:444\u2013461","journal-title":"Pharmacotherapy"},{"key":"4298_CR105","doi-asserted-by":"crossref","unstructured":"Kanj SS, Bassetti M, Kiratisin P, et al (2022) Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 60","DOI":"10.1016\/j.ijantimicag.2022.106633"},{"key":"4298_CR106","doi-asserted-by":"crossref","unstructured":"Karaiskos I, Lagou S, Pontikis K, et al (2019) The \u201cOld\u201d and the \u201cNew\u201d antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Front Public Health 7","DOI":"10.3389\/fpubh.2019.00151"},{"key":"4298_CR107","doi-asserted-by":"crossref","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI (2022) Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics 11","DOI":"10.3390\/antibiotics11060723"},{"key":"4298_CR108","doi-asserted-by":"crossref","unstructured":"Karasi\u0144ski M, Wnorowska U, Durna\u015b B, et al (2023) Ceragenins and Ceragenin-Based Core-Shell Nanosystems as New Antibacterial Agents against Gram-Negative Rods Causing Nosocomial Infections. Pathogens 12","DOI":"10.3390\/pathogens12111346"},{"key":"4298_CR109","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00472-17","author":"JA Karlowsky","year":"2017","unstructured":"Karlowsky JA, Kazmierczak KM, De Jonge BLM et al (2017) In vitro activity of aztreonam-avibactam against enterobacteriaceae and pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00472-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR110","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00169-18","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Lob SH, Kazmierczak KM et al (2018a) In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00169-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR111","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jgar.2018.07.012","volume":"15","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Lob SH, Young K et al (2018b) Activity of imipenem\/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015\u20132016. J Glob Antimicrob Resist 15:140\u2013147. https:\/\/doi.org\/10.1016\/j.jgar.2018.07.012","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR112","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","volume":"53","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Hackel MA, Tsuji M et al (2019) In Vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in north America and Europe in 2015\u20132016: SIDERO-WT-2015. Int J Antimicrob Agents 53:456\u2013466. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.007","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR113","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jgar.2019.10.028","volume":"21","author":"JA Karlowsky","year":"2020","unstructured":"Karlowsky JA, Lob SH, Kazmierczak KM et al (2020a) In vitro activity of imipenem\/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015\u20132017. J Glob Antimicrob Resist 21:223\u2013228. https:\/\/doi.org\/10.1016\/j.jgar.2019.10.028","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02135-z","author":"JA Karlowsky","year":"2021","unstructured":"Karlowsky JA, Lob SH, Young K et al (2021) Activity of ceftolozane\/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections \u2013 SMART United States 2018\u20132019. BMC Microbiol. https:\/\/doi.org\/10.1186\/s12866-021-02135-z","journal-title":"BMC Microbiol"},{"key":"4298_CR115","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad080","author":"JA Karlowsky","year":"2023","unstructured":"Karlowsky JA, Lob SH, Estabrook MA et al (2023) Susceptibility profile and \u03b2-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane\/tazobactam and\/or imipenem\/relebactam - SMART 2016\u201321. JAC Antimicrob Resist. https:\/\/doi.org\/10.1093\/jacamr\/dlad080","journal-title":"JAC Antimicrob Resist"},{"key":"4298_CR116","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Lob SH, Raddatz J (2020) In Vitro Activity of Imipenem\/Relebactam and Ceftolozane\/Tazobactam against Clinical Isolates of Gram-Negative Bacilli with Difficult-to-Treat Resistance and Multidrug-Resistant Phenotypes-SMART United States 2015\u20132017","DOI":"10.1093\/cid\/ciaa381"},{"key":"4298_CR117","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Hackel MA, Takemura M, et al (2022) In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies","DOI":"10.1128\/AAC.01990-21"},{"key":"4298_CR118","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/antibiotics12040761","volume":"12","author":"M Karvouniaris","year":"2023","unstructured":"Karvouniaris M, Almyroudi MP, Abdul-aziz MH et al (2023) novel antimicrobial agents for Gram-negative pathogens. Antibiotics 12:761","journal-title":"Antibiotics"},{"key":"4298_CR119","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1089\/mdr.2019.0498","volume":"26","author":"U Kilic","year":"2020","unstructured":"Kilic U, Koroglu M, Olmez M, Altindis M (2020) Investigation of the in vitro effectiveness of aztreonam\/avibactam, colistin\/apramycin, and meropenem\/apramycin combinations against carbapenemase-producing, extensively drug-resistant klebsiella pneumoniae strains. Microb Drug Resist 26:1291\u20131297. https:\/\/doi.org\/10.1089\/mdr.2019.0498","journal-title":"Microb Drug Resist"},{"key":"4298_CR120","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/antibiotics10121506","volume":"10","author":"B Kocsis","year":"2021","unstructured":"Kocsis B, Guly\u00e1s D, Szab\u00f3 D (2021) Delafloxacin, finafloxacin, and zabofloxacin: Novel fluoroquinolones in the antibiotic pipeline. Antibiotics 10:1506","journal-title":"Antibiotics"},{"key":"4298_CR121","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","volume":"22","author":"N Kohira","year":"2020","unstructured":"Kohira N, Hackel MA, Ishioka Y et al (2020) Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist 22:738\u2013741. https:\/\/doi.org\/10.1016\/j.jgar.2020.07.009","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR122","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc et al (2019) Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 19:1299\u20131311. https:\/\/doi.org\/10.1016\/S1473-3099(19)30403-7","journal-title":"Lancet Infect Dis"},{"key":"4298_CR123","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijantimicag.2017.06.014","volume":"51","author":"M Kresken","year":"2018","unstructured":"Kresken M, K\u00f6rber-Irrgang B, Pfeifer Y, Werner G (2018) Activity of temocillin against CTX-M-producing Escherichia coli and Klebsiella pneumoniae from Germany. Int J Antimicrob Agents 51:159\u2013160","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106128","author":"M Kresken","year":"2020","unstructured":"Kresken M, Korte-Berwanger M, Gatermann SG et al (2020) In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106128","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105883","author":"SC Kuo","year":"2020","unstructured":"Kuo SC, Liu CE, Lu PL et al (2020) Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015\u20132016. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105883","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR126","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/jac\/dkq278","volume":"65","author":"D Landman","year":"2010","unstructured":"Landman D, Babu E, Shah N et al (2010) Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother 65:2123\u20132127. https:\/\/doi.org\/10.1093\/jac\/dkq278","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR127","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O et al (2015a) Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:4856\u20134860. https:\/\/doi.org\/10.1128\/AAC.00843-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR128","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1128\/AAC.00830-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O et al (2015b) Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 59:5029\u20135031. https:\/\/doi.org\/10.1128\/AAC.00830-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR129","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/jac\/dkt178","volume":"68","author":"DM Livermore","year":"2013","unstructured":"Livermore DM, Warner M, Mushtaq S (2013) Activity of MK-7655 combined with imipenem against enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286\u20132290. https:\/\/doi.org\/10.1093\/jac\/dkt178","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR130","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/jac\/dky363","volume":"73","author":"DM Livermore","year":"2018","unstructured":"Livermore DM, Mushtaq S, Doumith M et al (2018) Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL-And AmpC-producing Enterobacteriaceae. J Antimicrob Chemother 73:3336\u20133345. https:\/\/doi.org\/10.1093\/jac\/dky363","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR131","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1099\/jmm.0.001142","volume":"69","author":"SH Lob","year":"2020","unstructured":"Lob SH, Karlowsky JA, Young K et al (2020) In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015\u20132017. J Med Microbiol 69:207\u2013217","journal-title":"J Med Microbiol"},{"key":"4298_CR132","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17","author":"O Lomovskaya","year":"2017","unstructured":"Lomovskaya O, Sun D, Rubio-Aparicio D et al (2017) Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01443-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR133","unstructured":"L\u00f3pez-Calleja AI, Morilla E, Rossi M, et al (2019) Antimicrobial activity of ceftolozanetazobactam against multidrug-resistant and extensively drugresistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital."},{"key":"4298_CR134","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-P\u00e9rez M, Haro-Moreno JM, Molina-Pardines C, et al (2021) Genomic Characterization of Imipenem-and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa","DOI":"10.1128\/mSphere.00836-21"},{"key":"4298_CR135","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1128\/AAC.00049-14","volume":"58","author":"C Lucasti","year":"2014","unstructured":"Lucasti C, Hershberger E, Miller B et al (2014) Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 58:5350\u20135357. https:\/\/doi.org\/10.1128\/AAC.00049-14","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR136","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/jac\/dkae072","volume":"79","author":"E Mallart","year":"2024","unstructured":"Mallart E, Guerin F, Amoura A et al (2024) Impact of the phenotypic expression of temocillin resistance in Escherichia coli on temocillin efficacy in a murine peritonitis model. J Antimicrob Chemother 79:1051\u20131059. https:\/\/doi.org\/10.1093\/jac\/dkae072","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR137","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/ajhp\/zxab012","volume":"78","author":"H Mansour","year":"2021","unstructured":"Mansour H, El Ouweini A, Chahine EB, Karaoui LR (2021) Imipenem\/cilastatin\/relebactam: A new carbapenem \u03b2-lactamase inhibitor combination. Am J Health Syst Pharm 78:674\u2013683","journal-title":"Am J Health Syst Pharm"},{"key":"4298_CR138","doi-asserted-by":"publisher","first-page":"105891","DOI":"10.1016\/j.ijantimicag.2020.105891","volume":"55","author":"AE Maraolo","year":"2020","unstructured":"Maraolo AE, Mazzitelli M, Trecarichi EM et al (2020) Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. Int J Antimicrob Agents 55:105891","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR139","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2217\/fmb-2023-0197","volume":"19","author":"I Martin-Loeches","year":"2024","unstructured":"Martin-Loeches I, Bruno CJ, DeRyke CA (2024) Perspectives on the use of ceftolozane\/tazobactam: a review of clinical trial data and real-world evidence. Future Microbiol 19:465","journal-title":"Future Microbiol"},{"key":"4298_CR140","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1021\/acsomega.0c05590","volume":"6","author":"A Matamoros-Recio","year":"2021","unstructured":"Matamoros-Recio A, Franco-Gonzalez JF, Forgione RE et al (2021) Understanding the antibacterial resistance: computational explorations in bacterial membranes. ACS Omega 6:6041\u20136054","journal-title":"ACS Omega"},{"key":"4298_CR141","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1093\/jac\/dkaa176","volume":"75","author":"P Matzneller","year":"2020","unstructured":"Matzneller P, Pokem PN, Capron A et al (2020) Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. J Antimicrob Chemother 75:2650\u20132656. https:\/\/doi.org\/10.1093\/jac\/dkaa176","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR142","doi-asserted-by":"crossref","unstructured":"Mauri C, Maraolo AE, Di Bella S, et al (2021) The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing Gram-negatives: A systematic review of in vitro studies and clinical cases. Antibiotics 10","DOI":"10.3390\/antibiotics10081012"},{"key":"4298_CR143","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00772-17","author":"S McCurdy","year":"2017","unstructured":"McCurdy S, Lawrence L, Quintas M et al (2017) In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00772-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR144","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jgar.2019.09.016","volume":"20","author":"HC Mirza","year":"2020","unstructured":"Mirza HC, Horta\u00e7 E, Ko\u00e7ak AA et al (2020) In vitro activity of ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study. J Glob Antimicrob Resist 20:334\u2013338. https:\/\/doi.org\/10.1016\/j.jgar.2019.09.016","journal-title":"J Glob Antimicrob Resist"},{"issue":"10","key":"4298_CR145","doi-asserted-by":"publisher","first-page":"001592","DOI":"10.1099\/jmm.0.001592","volume":"71","author":"HC Mirza","year":"2022","unstructured":"Mirza HC, G\u00fc\u00e7l\u00fc A\u00dc, \u0130nce Ceviz G, Ba\u015fustao\u011flu A (2022) Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of K. pneumoniae. J Med Microbiol 71(10):001592","journal-title":"J Med Microbiol"},{"key":"4298_CR146","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jac\/dkx543","volume":"73","author":"BT Mogle","year":"2018","unstructured":"Mogle BT, Steele JM, Thomas SJ et al (2018) Clinical review of delafloxacin: A novel anionic fluoroquinolone. J Antimicrob Chemother 73:1439\u20131451","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR147","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01649-20","author":"CP Morris","year":"2020","unstructured":"Morris CP, Bergman Y, Tekle T et al (2020) Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol. https:\/\/doi.org\/10.1128\/JCM.01649-20","journal-title":"J Clin Microbiol"},{"key":"4298_CR148","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jac\/dkaa456","volume":"76","author":"S Mushtaq","year":"2021","unstructured":"Mushtaq S, Meunier D, Vickers A et al (2021) Activity of imipenem\/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. J Antimicrob Chemother 76:434\u2013442. https:\/\/doi.org\/10.1093\/jac\/dkaa456","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107081","author":"S Mushtaq","year":"2024","unstructured":"Mushtaq S, Vickers A, Woodford N, Livermore DM (2024) Activity of aztreonam\/avibactam and ceftazidime\/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107081","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR150","doi-asserted-by":"crossref","unstructured":"Mushtaq S, Sadouki Z, Vickers A, et al (2020) In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria","DOI":"10.1128\/AAC.01582-20"},{"key":"4298_CR151","doi-asserted-by":"publisher","unstructured":"Nelson K, Hemarajata P, Sun D, et al (2017) Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. https:\/\/doi.org\/10.1128\/AAC","DOI":"10.1128\/AAC"},{"key":"4298_CR152","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1515\/hsz-2013-0292","volume":"395","author":"F Nguyen","year":"2014","unstructured":"Nguyen F, Starosta AL, Arenz S et al (2014) Tetracycline antibiotics and resistance mechanisms. Biol Chem 395:559\u2013575","journal-title":"Biol Chem"},{"key":"4298_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2022.154585","author":"TD Nguyen","year":"2022","unstructured":"Nguyen TD, Itayama T, Ramaraj R et al (2022) Physiological response of Simocephalus vetulus to five antibiotics and their mixture under 48-h acute exposure. Sci Total Environ. https:\/\/doi.org\/10.1016\/j.scitotenv.2022.154585","journal-title":"Sci Total Environ"},{"key":"4298_CR154","doi-asserted-by":"crossref","unstructured":"Nordmann P, Yao Y, Falgenhauer L, et al (2021) Recent emergence of aztreonam-avibactam resistance in NDM and OXA-48 carbapenemase-producing Escherichia coli in Germany. Antimicrob Agents Chemother 65","DOI":"10.1128\/AAC.01090-21"},{"key":"4298_CR155","doi-asserted-by":"crossref","unstructured":"Nurjadi D, Kocer K, Chanthalangsy Q, et al (2022) New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae","DOI":"10.1128\/aac.02011-21"},{"key":"4298_CR156","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1556\/030.2020.01152","volume":"67","author":"D O\u2019Neall","year":"2020","unstructured":"O\u2019Neall D, Juhasz E, Toth A et al (2020) Ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary. Acta Microbiol Immunol Hung 67:61\u201365. https:\/\/doi.org\/10.1556\/030.2020.01152","journal-title":"Acta Microbiol Immunol Hung"},{"key":"4298_CR157","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/jac\/dkn136","volume":"62","author":"R Okumura","year":"2008","unstructured":"Okumura R, Hirata T, Onodera Y et al (2008) Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: Contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 62:98\u2013104. https:\/\/doi.org\/10.1093\/jac\/dkn136","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR158","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/jac\/dkz149","volume":"74","author":"J-M Ortiz De La Rosa","year":"2019","unstructured":"Ortiz De La Rosa J-M, Nordmann P, Poirel L (2019) ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother 74:1934\u20131939","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR159","doi-asserted-by":"publisher","first-page":"229","DOI":"10.30934\/kusbed.1163427","volume":"8","author":"S \u00d6zta\u015f","year":"2022","unstructured":"\u00d6zta\u015f S, Er DK, D\u00fcndar D (2022) Resistance rates of carbapenem-resistant and -susceptible klebsiella pneumoniae isolates to various antimicrobials. Journal of Health Sciences Kocaeli University 8:229\u2013232. https:\/\/doi.org\/10.30934\/kusbed.1163427","journal-title":"Journal of Health Sciences Kocaeli University"},{"issue":"2","key":"4298_CR160","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1556\/030.2024.02292","volume":"71","author":"S \u00d6zta\u015f","year":"2024","unstructured":"\u00d6zta\u015f S, Er DK, D\u00fcndar D, Ke\u00e7eli S (2024) Efficacy of ceftazidime\/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli. Acta Microbiol Immunol Hung 71(2):110\u2013120","journal-title":"Acta Microbiol Immunol Hung"},{"key":"4298_CR161","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1128\/AAC.01585-15","volume":"60","author":"JM Pag\u00e8s","year":"2016","unstructured":"Pag\u00e8s JM, Peslier S, Keating TA et al (2016) Role of the outer membrane and porins in susceptibility of \u03b2-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob Agents Chemother 60:1349\u20131359. https:\/\/doi.org\/10.1128\/AAC.01585-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR162","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.idc.2020.05.001","volume":"34","author":"KM Papp-Wallace","year":"2020","unstructured":"Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA (2020) Resistance to Novel \u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor Combinations: The \u201cPrice of Progress.\u201d Infect Dis Clin North Am 34:773\u2013819","journal-title":"Infect Dis Clin North Am"},{"key":"4298_CR163","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2147\/IDR.S150447","volume":"11","author":"LA Petty","year":"2018","unstructured":"Petty LA, Henig O, Patel TS et al (2018) Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant enterobacteriaceae. Infect Drug Resist 11:1461\u20131472","journal-title":"Infect Drug Resist"},{"key":"4298_CR164","doi-asserted-by":"crossref","unstructured":"Philippon A, Arlet G, Labia R, Iorga BI (2022) Class C b-Lactamases: Molecular Characteristics. Clin Microbiol Rev 35","DOI":"10.1128\/cmr.00150-21"},{"key":"4298_CR165","unstructured":"P\u0131narl\u0131k F., G\u00f6\u00e7er L. S., Af\u015farlar H., et al (2024) Emerging resistance against new antibiotics in carbapenem resistant Pseudomonas aeruginosa infections. 34th ECCMID, Barcelona, Spain"},{"key":"4298_CR166","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eimce.2022.06.014","volume":"41","author":"V Pintado","year":"2023","unstructured":"Pintado V, Ruiz-Garbajosa P, Aguilera-Alonso D et al (2023) Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria. Enfermedades Infecciosas y Microbiologia Clinica (English Ed) 41:360\u2013370. https:\/\/doi.org\/10.1016\/j.eimce.2022.06.014","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica (English Ed)"},{"key":"4298_CR167","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","volume":"71","author":"JM Pogue","year":"2020","unstructured":"Pogue JM, Kaye KS, Veve MP et al (2020) Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 71:304\u2013310. https:\/\/doi.org\/10.1093\/cid\/ciz816","journal-title":"Clin Infect Dis"},{"key":"4298_CR168","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","volume":"41","author":"L Poirel","year":"2022","unstructured":"Poirel L, Sadek M, Kusaksizoglu A, Nordmann P (2022) Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur J Clin Microbiol Infect Dis 41:677\u2013680. https:\/\/doi.org\/10.1007\/s10096-021-04397-x","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4298_CR169","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1319\u20131328. https:\/\/doi.org\/10.1016\/S1473-3099(18)30554-1","journal-title":"Lancet Infect Dis"},{"key":"4298_CR170","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00258-24","author":"S Qiao","year":"2024","unstructured":"Qiao S, Xin S, Zhu Y et al (2024) A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae. Microbiol Spectr. https:\/\/doi.org\/10.1128\/spectrum.00258-24","journal-title":"Microbiol Spectr"},{"key":"4298_CR171","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dks307","volume":"67","author":"JM Remy","year":"2012","unstructured":"Remy JM, Tow-Keogh CA, McConnell TS et al (2012) Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: Resistance selection and characterization. J Antimicrob Chemother 67:2814\u20132820. https:\/\/doi.org\/10.1093\/jac\/dks307","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jointm.2023.12.007","author":"C Roger","year":"2024","unstructured":"Roger C (2024) Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review. Journal of Intensive Medicine. https:\/\/doi.org\/10.1016\/j.jointm.2023.12.007","journal-title":"Journal of Intensive Medicine"},{"key":"4298_CR173","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.bjid.2017.03.008","volume":"21","author":"F Rossi","year":"2017","unstructured":"Rossi F, Cury AP, Franco MRG et al (2017) The in vitro activity of ceftazidime\u2013avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in S\u00e3o Paulo, Brazil. Brazilian Journal of Infectious Diseases 21:569\u2013573","journal-title":"Brazilian Journal of Infectious Diseases"},{"key":"4298_CR174","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jgar.2022.06.018","volume":"30","author":"GM Rossolini","year":"2022","unstructured":"Rossolini GM, Stone G, Kantecki M, Arhin FF (2022) In vitro activity of aztreonam\/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019. J Glob Antimicrob Resist 30:214\u2013221. https:\/\/doi.org\/10.1016\/j.jgar.2022.06.018","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR175","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1093\/jac\/dkaa278","volume":"75","author":"HS Sader","year":"2020","unstructured":"Sader HS, Carvalhaes CG, Duncan LR et al (2020) Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012\u201318. J Antimicrob Chemother 75:2907\u20132913","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR176","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1089\/mdr.2020.0217","volume":"27","author":"HS Sader","year":"2021","unstructured":"Sader HS, Carvalhaes CG, Streit JM et al (2021) Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016\u20132018. Microb Drug Resist 27:342\u2013349","journal-title":"Microb Drug Resist"},{"key":"4298_CR177","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad032","author":"HS Sader","year":"2023","unstructured":"Sader HS, Castanheira M, Kimbrough JH et al (2023) Aztreonam\/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019\u201321). JAC Antimicrob Resist. https:\/\/doi.org\/10.1093\/jacamr\/dlad032","journal-title":"JAC Antimicrob Resist"},{"key":"4298_CR178","doi-asserted-by":"publisher","unstructured":"Sain B, Sharma V, Kumar Sharma A, et al (2018) Dalafloxacin-Antibacterial:A Review. International Journal of Research -GRANTHAALAYAH 6:91\u2013101. https:\/\/doi.org\/10.29121\/granthaalayah.v6.i1.2018.1597","DOI":"10.29121\/granthaalayah.v6.i1.2018.1597"},{"key":"4298_CR179","doi-asserted-by":"crossref","unstructured":"Sangiorgio G, Calvo M, Stefani S (2024) Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing Gram-negative bacteria: a comprehensive review. Clin Microbiol Infect","DOI":"10.1016\/j.cmi.2024.11.006"},{"key":"4298_CR180","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1093\/cid\/ciz826","volume":"69","author":"T Sato","year":"2019","unstructured":"Sato T, Yamawaki K (2019) Cefiderocol: Discovery, Chemistry, and in Vivo Profiles of a Novel Siderophore Cephalosporin. Clin Infect Dis 69:S538\u2013S543. https:\/\/doi.org\/10.1093\/cid\/ciz826","journal-title":"Clin Infect Dis"},{"key":"4298_CR181","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/23744235.2019.1653491","volume":"51","author":"E Savov","year":"2019","unstructured":"Savov E, Trifonova A, Kovachka K et al (2019) Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa\u2013a pilot Bulgarian study. Infect Dis 51:870\u2013873","journal-title":"Infect Dis"},{"key":"4298_CR182","doi-asserted-by":"crossref","unstructured":"Schmidt-Malan SM, Mishra AJ, Mushtaq A, et al (2018) In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli","DOI":"10.1128\/AAC.00533-18"},{"key":"4298_CR183","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","volume":"79","author":"LJ Scott","year":"2019","unstructured":"Scott LJ (2019) Eravacycline: A Review in Complicated Intra-Abdominal Infections. Drugs 79:315\u2013324","journal-title":"Drugs"},{"key":"4298_CR184","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/phar.2203","volume":"39","author":"KM Shaeer","year":"2019","unstructured":"Shaeer KM, Zmarlicka MT, Chahine EB et al (2019) Plazomicin: A Next-Generation Aminoglycoside. Pharmacotherapy 39:77\u201393","journal-title":"Pharmacotherapy"},{"key":"4298_CR185","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/jac\/dkx066","volume":"72","author":"Z Shen","year":"2017","unstructured":"Shen Z, Ding B, Ye M et al (2017) High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime\/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 72:1930\u20131936. https:\/\/doi.org\/10.1093\/jac\/dkx066","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR186","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G et al (2016) Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin Infect Dis 63:1615\u20131618. https:\/\/doi.org\/10.1093\/cid\/ciw636","journal-title":"Clin Infect Dis"},{"key":"4298_CR187","doi-asserted-by":"publisher","DOI":"10.1128\/AAC","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen H, Chen L et al (2017a). Ceftazidime-Avibactam is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella Pneumoniae Bacteremia. https:\/\/doi.org\/10.1128\/AAC","journal-title":"Ceftazidime-Avibactam is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella Pneumoniae Bacteremia"},{"key":"4298_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofx101","volume":"4","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Press EG et al (2017b) Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiellapneumoniae carbapenemase- producing K pneumoniae: A case report and review of literature. Open Forum Infect Dis 4:1\u20134. https:\/\/doi.org\/10.1093\/ofid\/ofx101","journal-title":"Open Forum Infect Dis"},{"key":"4298_CR189","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/cid\/ciz1131","volume":"71","author":"RK Shields","year":"2020","unstructured":"Shields RK, McCreary EK, Marini RV et al (2020) Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis 71:667\u2013671. https:\/\/doi.org\/10.1093\/cid\/ciz1131","journal-title":"Clin Infect Dis"},{"key":"4298_CR190","doi-asserted-by":"publisher","unstructured":"Shields RK, Nguyen H, Chen L, et al (2018) Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. https:\/\/doi.org\/10.1128\/AAC","DOI":"10.1128\/AAC"},{"key":"4298_CR191","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.clinthera.2020.01.023","volume":"42","author":"BR Shoulders","year":"2020","unstructured":"Shoulders BR, Casapao AM, Venugopalan V (2020) An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Clin Ther 42:692\u2013702","journal-title":"Clin Ther"},{"key":"4298_CR192","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1093\/jac\/dkz379","volume":"74","author":"MA Sid Ahmed","year":"2019","unstructured":"Sid Ahmed MA, Abdel Hadi H, Hassan AAI et al (2019) Evaluation of in vitro activity of ceftazidime\/avibactam and ceftolozane\/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. J Antimicrob Chemother 74:3497\u20133504. https:\/\/doi.org\/10.1093\/jac\/dkz379","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR193","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/cid\/ciab888","volume":"75","author":"PJ Simner","year":"2022","unstructured":"Simner PJ, Mostafa HH, Bergman Y et al (2022) Progressive Development of Cefiderocol Resistance in Escherichia coli during Therapy is Associated with an Increase in blaNDM-5Copy Number and Gene Expression. Clin Infect Dis 75:47\u201354. https:\/\/doi.org\/10.1093\/cid\/ciab888","journal-title":"Clin Infect Dis"},{"key":"4298_CR194","doi-asserted-by":"publisher","unstructured":"Simner PJ, Beisken S, Bergman Y, et al (2021) Cefiderocol Activity against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance. Open Forum Infect Dis 8:. https:\/\/doi.org\/10.1093\/ofid\/ofab311","DOI":"10.1093\/ofid\/ofab311"},{"key":"4298_CR195","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1128\/AAC.02798-15","volume":"60","author":"OO Soge","year":"2016","unstructured":"Soge OO, Salipante SJ, No D et al (2016) In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother 60:3106\u20133111. https:\/\/doi.org\/10.1128\/AAC.02798-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR196","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/jac\/dky204","volume":"73","author":"GG Stone","year":"2018","unstructured":"Stone GG, Newell P, Gasink LB et al (2018) Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: Pooled data from the ceftazidime\/avibactam Phase III clinical trial programme. J Antimicrob Chemother 73:2519\u20132523. https:\/\/doi.org\/10.1093\/jac\/dky204","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR197","doi-asserted-by":"publisher","DOI":"10.1128\/AAC","author":"D Sun","year":"2017","unstructured":"Sun D, Rubio-Aparicio D, Nelson K et al (2017) Meropenem-Vaborbactam Resistance Selection. Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella Pneumoniae. https:\/\/doi.org\/10.1128\/AAC","journal-title":"Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella Pneumoniae"},{"key":"4298_CR198","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02293-0","author":"L Sun","year":"2021","unstructured":"Sun L, Li H, Wang Q et al (2021) Increased gene expression and copy number of mutated bla KPC lead to high-level ceftazidime\/avibactam resistance in Klebsiella pneumoniae. BMC Microbiol. https:\/\/doi.org\/10.1186\/s12866-021-02293-0","journal-title":"BMC Microbiol"},{"key":"4298_CR199","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5937\/galmed2305014s","volume":"2","author":"M \u0160urbatovi\u0107","year":"2023","unstructured":"\u0160urbatovi\u0107 M, Peri\u0107 A, Raki\u0107 G, Jev\u0111i\u0107 J (2023) Antibiotic treatment of critically ill patients with sepsis: From FK\/FD to novel drugs. Galenika Medical Journal 2:14\u201322. https:\/\/doi.org\/10.5937\/galmed2305014s","journal-title":"Galenika Medical Journal"},{"key":"4298_CR200","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A et al (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318\u2013327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3","journal-title":"Lancet Infect Dis"},{"key":"4298_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-023-00573-3","author":"R Taha","year":"2023","unstructured":"Taha R, Kader O, Shawky S, Rezk S (2023) Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope. Ann Clin Microbiol Antimicrob. https:\/\/doi.org\/10.1186\/s12941-023-00573-3","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"4298_CR202","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA et al (2022) Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 75:187\u2013212. https:\/\/doi.org\/10.1093\/cid\/ciac268","journal-title":"Clin Infect Dis"},{"key":"4298_CR203","doi-asserted-by":"publisher","unstructured":"Teo JQ-M, Lim JC, Tang CY, et al (2021) Ceftolozane\/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. mSphere, https:\/\/doi.org\/10.1128\/msphere.01026-20","DOI":"10.1128\/msphere.01026-20"},{"key":"4298_CR204","doi-asserted-by":"crossref","unstructured":"Terreni M, Taccani M, Pregnolato M (2021) New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives. Molecules 26","DOI":"10.3390\/molecules26092671"},{"key":"4298_CR205","doi-asserted-by":"publisher","first-page":"I47","DOI":"10.1093\/jac\/dkaa497","volume":"76","author":"U Theuretzbacher","year":"2021","unstructured":"Theuretzbacher U, Carrara E, Conti M, Tacconelli E (2021) Role of new antibiotics for KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 76:I47\u2013I54. https:\/\/doi.org\/10.1093\/jac\/dkaa497","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR206","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005932","author":"ZX Tian","year":"2016","unstructured":"Tian ZX, Yi XX, Cho A et al (2016) CpxR Activates MexAB-OprM Efflux Pump Expression and Enhances Antibiotic Resistance in Both Laboratory and Clinical nalB-Type Isolates of Pseudomonas aeruginosa. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1005932","journal-title":"PLoS Pathog"},{"key":"4298_CR207","doi-asserted-by":"publisher","first-page":"E4539","DOI":"10.1093\/cid\/ciaa803","volume":"73","author":"I Titov","year":"2021","unstructured":"Titov I, Wunderink RG, Roquilly A et al (2021) A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis 73:E4539\u2013E4548. https:\/\/doi.org\/10.1093\/cid\/ciaa803","journal-title":"Clin Infect Dis"},{"key":"4298_CR208","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1093\/cid\/ciy1079","volume":"68","author":"PM Tulkens","year":"2019","unstructured":"Tulkens PM, Van Bambeke F, Zinner SH (2019) Profile of a novel anionic fluoroquinolone - Delafloxacin. Clin Infect Dis 68:S213\u2013S222. https:\/\/doi.org\/10.1093\/cid\/ciy1079","journal-title":"Clin Infect Dis"},{"key":"4298_CR209","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bjid.2020.04.004","volume":"24","author":"FF Tuon","year":"2020","unstructured":"Tuon FF, Cieslinski J, da Rodrigues S, S, et al (2020) Evaluation of in vitro activity of ceftolozane\u2013tazobactam against recent clinical bacterial isolates from Brazil \u2013 the EM200 study. Brazilian Journal of Infectious Diseases 24:96\u2013103. https:\/\/doi.org\/10.1016\/j.bjid.2020.04.004","journal-title":"Brazilian Journal of Infectious Diseases"},{"key":"4298_CR210","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/antibiotics12081241","volume":"12","author":"A Turban","year":"2023","unstructured":"Turban A, Gu\u00e9rin F, Dinh A, Cattoir V (2023) Updated Review on Clinically-Relevant Properties of Delafloxacin. Antibiotics 12:1241","journal-title":"Antibiotics"},{"key":"4298_CR211","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jgar.2024.10.097","volume":"39","author":"FS T\u00fcrkdo\u011fan","year":"2024","unstructured":"T\u00fcrkdo\u011fan FS, Ongen B (2024) In Vitro Activities of Cefiderocol, Ceftazidime-Avibactam, Meropenem-Vaborbactam, Imipenem-Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae. Journal of Global Antimicrobial Resistance 39:31","journal-title":"Journal of Global Antimicrobial Resistance"},{"key":"4298_CR212","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2147\/IDR.S207993","volume":"12","author":"C Venditti","year":"2019","unstructured":"Venditti C, Nisii C, D\u2019arezzo S et al (2019) Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae. Infect Drug Resist 12:1935\u20131940. https:\/\/doi.org\/10.2147\/IDR.S207993","journal-title":"Infect Drug Resist"},{"key":"4298_CR213","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00588-23","author":"C Viguier","year":"2023","unstructured":"Viguier C, Bouvier M, Sadek M et al (2023) Rapid Aztreonam\/Avibactam NP test for detection of aztreonam\/ avibactam susceptibility\/resistance in Enterobacterales. J Clin Microbiol. https:\/\/doi.org\/10.1128\/jcm.00588-23","journal-title":"J Clin Microbiol"},{"key":"4298_CR214","doi-asserted-by":"crossref","unstructured":"Walkty A, Karlowsky JA, Baxter MR, et al (2019) In vitro activity of plazomicin against Gram-negative and Gram-positive bacterial pathogens isolated from patients in Canadian hospitals from 2013 to 2017 as part of the CANWARD surveillance study. Antimicrob Agents Chemother 63","DOI":"10.1128\/AAC.02068-18"},{"key":"4298_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03205-z","author":"R Wang","year":"2018","unstructured":"Wang R, Van Dorp L, Shaw LP et al (2018) The global distribution and spread of the mobilized colistin resistance gene mcr-1. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-018-03205-z","journal-title":"Nat Commun"},{"key":"4298_CR216","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02670-21","author":"Q Wang","year":"2022","unstructured":"Wang Q, Jin L, Sun S et al (2022) Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network. Microbiol Spectr. https:\/\/doi.org\/10.1128\/spectrum.02670-21","journal-title":"Microbiol Spectr"},{"key":"4298_CR217","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13756-025-01518-5","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Sholeh M, Yang L et al (2025) Global trends of ceftazidime\u2013avibactam resistance in Gram-negative bacteria: systematic review and meta-analysis. Antimicrob Resist Infect Control 14:10. https:\/\/doi.org\/10.1186\/s13756-025-01518-5","journal-title":"Antimicrob Resist Infect Control"},{"key":"4298_CR218","unstructured":"WHO (2020) World Health Organization: Antimicrobial resistance surveillance in Europe 2022 \u2013 2020 data. https:\/\/iris.who.int\/handle\/10665\/351141. Accessed 20 Feb 2025"},{"key":"4298_CR219","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jgar.2024.06.007","volume":"38","author":"CM Wilhelm","year":"2024","unstructured":"Wilhelm CM, Antochevis LC, Magagnin CM et al (2024) Susceptibility evaluation of novel beta-lactam\/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil. J Glob Antimicrob Resist 38:247\u2013251. https:\/\/doi.org\/10.1016\/j.jgar.2024.06.007","journal-title":"J Glob Antimicrob Resist"},{"key":"4298_CR220","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1093\/jac\/dkv094","volume":"70","author":"ML Winkler","year":"2015","unstructured":"Winkler ML, Papp-Wallace KM, Bonomo RA (2015a) Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop. J Antimicrob Chemother 70:2279\u20132286. https:\/\/doi.org\/10.1093\/jac\/dkv094","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR221","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1128\/AAC.04238-14","volume":"59","author":"ML Winkler","year":"2015","unstructured":"Winkler ML, Papp-Wallace KM, Hujer AM et al (2015b) Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: Resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59:1020\u20131029. https:\/\/doi.org\/10.1128\/AAC.04238-14","journal-title":"Antimicrob Agents Chemother"},{"key":"4298_CR222","doi-asserted-by":"crossref","unstructured":"Wu S, Zong Z (2022) Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistance. Precis Clin Med 5","DOI":"10.1093\/pcmedi\/pbac029"},{"key":"4298_CR223","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M et al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21:213\u2013225. https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"key":"4298_CR224","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.eng.2020.11.004","volume":"11","author":"T Xu","year":"2022","unstructured":"Xu T, Guo Y, Ji Y et al (2022) Epidemiology and Mechanisms of Ceftazidime-Avibactam Resistance in Gram-Negative Bacteria. Engineering 11:138\u2013145","journal-title":"Engineering"},{"key":"4298_CR225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2021","unstructured":"Yahav D, Giske CG, Gramatniece A et al (2021) New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations. Clin Microbiol Rev 34:1\u201361. https:\/\/doi.org\/10.1128\/CMR.00115-20","journal-title":"Clin Microbiol Rev"},{"key":"4298_CR226","doi-asserted-by":"publisher","first-page":"S427","DOI":"10.1093\/cid\/ciaa1519","volume":"71","author":"Q Yang","year":"2020","unstructured":"Yang Q, Zhang H, Yu Y et al (2020) In vitro activity of imipenem\/relebactam against enterobacteriaceae isolates obtained from intra-Abdominal, respiratory tract, and urinary tract infections in china: Study for monitoring antimicrobial resistance trends (smart), 2015\u20132018. Clin Infect Dis 71:S427\u2013S435. https:\/\/doi.org\/10.1093\/cid\/ciaa1519","journal-title":"Clin Infect Dis"},{"key":"4298_CR227","doi-asserted-by":"crossref","unstructured":"Yao J, Wang J, Chen M, Cai Y (2021) Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms. Front Med (Lausanne) 8","DOI":"10.3389\/fmed.2021.741940"},{"key":"4298_CR228","unstructured":"Yoshiaki Gu (2020) Raising awareness of antimicrobialresistance: comment on\u2018Reducingexpectations for antibiotics in primary care:a randomised experiment to test theresponse to fear based messages aboutantimicrobial resistance.\u2019 GuBMC Medicine"},{"key":"4298_CR229","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1522-7","author":"K Young","year":"2019","unstructured":"Young K, Painter RE, Raghoobar SL et al (2019) In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol. https:\/\/doi.org\/10.1186\/s12866-019-1522-7","journal-title":"BMC Microbiol"},{"key":"4298_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.926209","author":"W Yu","year":"2022","unstructured":"Yu W, Shen P, Chen Y et al (2022) Epidemiology and genomic characteristics of bloodstream infection caused by carbapenem-resistant klebsiella pneumoniae with decreased susceptibility to aztreonam\/avibactam in China. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2022.926209","journal-title":"Front Cell Infect Microbiol"},{"key":"4298_CR231","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10051068","volume":"10","author":"E Yusuf","year":"2021","unstructured":"Yusuf E, Bax HI, Verkaik NJ, van Westreenen M (2021) An update on eight \u201cnew\u201d antibiotics against multidrug-resistant Gram-negative bacteria. J Clin Med 10:1\u201322","journal-title":"J Clin Med"},{"key":"4298_CR232","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ijantimicag.2019.02.022","volume":"53","author":"R Zamudio","year":"2019","unstructured":"Zamudio R, Hijazi K, Joshi C et al (2019) Phylogenetic analysis of resistance to ceftazidime\/avibactam, ceftolozane\/tazobactam and carbapenems in piperacillin\/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients. Int J Antimicrob Agents 53:774\u2013780. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.02.022","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR233","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","volume":"74","author":"GG Zhanel","year":"2014","unstructured":"Zhanel GG, Chung P, Adam H et al (2014) Ceftolozane\/tazobactam: A novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 74:31\u201351","journal-title":"Drugs"},{"key":"4298_CR234","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.diagmicrobio.2017.12.013","volume":"91","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Baxter MR, Adam HJ et al (2018a) In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014\u20132015. Diagn Microbiol Infect Dis 91:55\u201362. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.12.013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4298_CR235","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H et al (2018b) Imipenem-Relebactam and Meropenem\u2013Vaborbactam: Two Novel Carbapenem-\u03b2-Lactamase Inhibitor Combinations. Drugs 78:65\u201398","journal-title":"Drugs"},{"key":"4298_CR236","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenitsky S et al (2019) Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 79:271\u2013289","journal-title":"Drugs"},{"key":"4298_CR237","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/jac\/dkx261","volume":"72","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kashikar A, Bush K (2017) In vitro activity of plazomicin against \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). J Antimicrob Chemother 72:2792\u20132795. https:\/\/doi.org\/10.1093\/jac\/dkx261","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR238","doi-asserted-by":"publisher","first-page":"124.e1","DOI":"10.1016\/j.cmi.2019.08.020","volume":"26","author":"P Zhang","year":"2020","unstructured":"Zhang P, Shi Q, Hu H et al (2020) Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect 26:124.e1-124.e4. https:\/\/doi.org\/10.1016\/j.cmi.2019.08.020","journal-title":"Clin Microbiol Infect"},{"key":"4298_CR239","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","volume":"52","author":"H Zhong","year":"2018","unstructured":"Zhong H, Zhao XY, Zhang ZL et al (2018) Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis. Int J Antimicrob Agents 52:443\u2013450","journal-title":"Int J Antimicrob Agents"},{"key":"4298_CR240","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1093\/jac\/dky251","volume":"73","author":"M Zhou","year":"2018","unstructured":"Zhou M, Yang Q, Lomovskaya O et al (2018) In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China. J Antimicrob Chemother 73:2789\u20132796. https:\/\/doi.org\/10.1093\/jac\/dky251","journal-title":"J Antimicrob Chemother"},{"key":"4298_CR241","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/23744235.2015.1087648","volume":"48","author":"IN Zykov","year":"2016","unstructured":"Zykov IN, Sundsfjord A, Sm\u00e5brekke L, Samuelsen \u00d8 (2016) The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010\u20132011. Infect Dis 48:99\u2013107. https:\/\/doi.org\/10.3109\/23744235.2015.1087648","journal-title":"Infect Dis"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04298-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-025-04298-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04298-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:06:35Z","timestamp":1745917595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-025-04298-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":240,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4298"],"URL":"https:\/\/doi.org\/10.1007\/s00203-025-04298-z","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"110"}}